Novo Nordisk repurchased 18,325,000 B shares for DKK 5,526,186,488
Novo Nordisk repurchased 18,325,000 B shares for DKK 5,526,186,488, raising treasury shares to 47,124,876 (1.1% of total capital).
Key points
- The company completed the repurchase of 18,325,000 B shares, paying DKK 5,526,186,488, and as of September 14, 2026 holds 47,124,876 B treasury shares, representing 1.1% of the total 4,465,000,000 shares.
- The repurchase programme was launched on 6 May 2026 in accordance with Article 5 of Regulation No 596/2014 (MAR) and the EU Delegated Regulation 2016/1052 (Safe Harbour rules, an EU safe‑harbour exemption under market abuse regulations).
- Novo Nordisk is a global health‑care leader founded in 1923, operating in 80 countries and selling products in about 170 countries; its B shares are listed on Nasdaq Copenhagen and its ADRs trade on the NYSE.
What happened
The company completed the repurchase of 18,325,000 B shares, paying DKK 5,526,186,488, and as of September 14, 2026 holds 47,124,876 B treasury shares, representing 1.1% of the total 4,465,000,000 shares.
Program conditions
The repurchase programme was launched on 6 May 2026 in accordance with Article 5 of Regulation No 596/2014 (MAR) and the EU Delegated Regulation 2016/1052 (Safe Harbour rules, an EU safe‑harbour exemption under market abuse regulations).
Company context
Novo Nordisk is a global health‑care leader founded in 1923, operating in 80 countries and selling products in about 170 countries; its B shares are listed on Nasdaq Copenhagen and its ADRs trade on the NYSE.
What to watch
Investors should monitor cash and treasury‑share levels in upcoming financial reports to assess the repurchase’s impact on liquidity and earnings per share (EPS).
Original sources
Cite this article
The fingerprint identifies the exact version of each original that the article was written from; the original stays at its source.
Follow Novo Nordisk A S
A notification in your browser or on your phone when we publish about Novo Nordisk A S. Free, no email, no account, no app.
Prepared by AI from official company documents; automatic checks and an AI editor review it before publication, and not every article is read by a person. This is not investment advice. Editorial standards
